Skip to main content
Premium Trial:

Request an Annual Quote

Genaco Biomedical Wins $99,000 SBIR Grant to Develop Bead-Based microRNA Expression Profiling Technology

NEW YORK, June 17 (GenomeWeb News) - Genaco Biomedical Products of Huntsville, Ala., has received a six-month Small Business Innovation Research grant worth $99,000 from the National Cancer Institute to develop a bead-based array system for the detection of microRNAs, according to NIH databases.

 

The company has already developed a method based on Luminex's xMAP platform that uses locked nucleic acid technology, according to the grant abstract. Genaco intends to use the system to develop an assay based on 20 cancer-related miRNA targets and to use this prototype assay to study cancer samples.

 

For more information, see an article in this week's RNAi News.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.